Profluent, a California-based AI-first protein design company, has developed an AI model capable of generating CRISPR-like proteins that do not occur naturally. These synthetic gene editors hold immense potential in developing treatments for previously incurable diseases. Profluent has also released OpenCRISPR-1, an initial open-source AI-created gene editor licensed for both research and commercial use.